Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response

Haematologica

Volumn 92, Issue 10, 2007, Pages 1415-1418

  Gertz, Morie A ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Kumar, Shaji K ^a   Leung, Nelson ^a   Gastineau, Dennis A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Chemotherapy; Complete response; Immunoglobulin free light chain; Stem cell transplant; Survival

Indexed keywords

MELPHALAN;

ADULT; AMYLOIDOSIS; APHERESIS; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMYLOIDOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36349007621     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11413     Document Type: Article

References (20)

1. Vesole DH, Perez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006;81:880-8.
2. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376:30-6.
3. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51:878-81.
4. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005;51:805-7.
5. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frondine therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004;22:1857-63.
6. Baldini L, Radaelli F, Chiorboli O, Fumagalli S, Cro L, Segala M, et al. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer 1991; 68:62-7.
7. Blade J, Esteve J, Rives S, Martinez C, Rovira M, Urbano-Ispizua A, et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission: results of a non-randomized study from a single institution. Bone Marrow Transplant 2000;26:845-9.
8. Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438-46.
9. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.
10. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
11. Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 2006;91:1635-43.
12. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubkeer L, Hermine O, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM Intergroup) [Abstract]. Blood 2005; 106:421.
13. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
14. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-64.
15. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36:597-600.
16. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378-83.
17. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8.
18. Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417-25.
19. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-31.
20. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361: 1787-9.